Actively Recruiting

Phase Not Applicable
Age: 50Years - 85Years
All Genders
NCT06618872

Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment

Led by University Hospital, Geneva · Updated on 2025-12-23

120

Participants Needed

2

Research Sites

142 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Geneva

Lead Sponsor

C

Centre Hospitalier Universitaire Vaudois

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia

CONDITIONS

Official Title

Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment

Who Can Participate

Age: 50Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent to participate
  • Between 50 and 85 years of age
  • Diagnosed with Mild Cognitive Impairment (at least one pathological neuropsychological test but no functional impairment) or mild dementia (both cognitive and functional impairments)
  • MRI scan available within 6 months before screening
  • Prescription for diagnostic amyloid PET scan
  • Willing and able to comply with study requirements as judged by investigator
Not Eligible

You will not qualify if you...

  • Presence of psychiatric disorders, extensive white matter lesions, or signs of vascular dementia
  • Visual or hearing problems that would affect neuropsychological testing
  • Participation in previous Alzheimer's disease clinical trials affecting amyloid or tau brain load
  • Participation in other trials or studies incompatible with [18F]RO948 imaging
  • Ferromagnetic implants or devices that make MRI scanning impossible
  • Women of childbearing potential who are pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Geneva University Hospital

Geneva, Canton of Geneva, Switzerland, 1205

Actively Recruiting

2

Centre Medical Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland, 1211

Actively Recruiting

Loading map...

Research Team

V

Valentina Garibotto, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment | DecenTrialz